These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 2123427)

  • 1. Preventing coronary artery reocclusion following t-PA.
    Sylvain Moore H
    Crit Care Nurse; 1990; 10(10):52-8. PubMed ID: 2123427
    [No Abstract]   [Full Text] [Related]  

  • 2. Care of the patient receiving recombinant tissue plasminogen activator.
    White-Williams C
    J Cardiovasc Nurs; 1989 Nov; 4(1):62-7. PubMed ID: 2513380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant tissue-type plasminogen activator in acute myocardial infarction: role of the critical care nurse.
    Kline EM
    Heart Lung; 1987 Nov; 16(6 Pt 2):779-86. PubMed ID: 2960639
    [No Abstract]   [Full Text] [Related]  

  • 4. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What you should know about thrombolytic therapy for acute MI.
    Aragon D; Martin M
    Am J Nurs; 1993 Sep; 93(9):24-31; quiz 33. PubMed ID: 8213959
    [No Abstract]   [Full Text] [Related]  

  • 6. Addendum: a standardized nursing care plan for the acute myocardial infarction patient receiving tissue-type plasminogen activator.
    Erickson DE; Kleven M
    Heart Lung; 1987 Nov; 16(6 Pt 2):794-800. PubMed ID: 3119524
    [No Abstract]   [Full Text] [Related]  

  • 7. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue plasminogen activator: the nurse's role.
    Lemmon PN; Kalman J; Zamary Sefcik K
    Crit Care Nurse; 1994 Dec; 14(6):22, 25-31. PubMed ID: 7712797
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].
    Cannas S; De Leo A; Marzari A
    G Ital Cardiol; 1997 Mar; 27(3):278-80. PubMed ID: 9244730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
    Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
    Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
    Glazier JJ; Crowley J; Cremin D; Coll T; Daly K
    Ir Med J; 1989 Sep; 82(3):111-4. PubMed ID: 2513287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reocclusion after treatment with actilyse].
    Raynaud P; Desveaux B
    Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():25-32. PubMed ID: 3142416
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulating appropriate nursing diagnoses for the patient receiving tissue-type plasminogen activator.
    Brooks-Brunn JA
    Heart Lung; 1987 Nov; 16(6 Pt 2):787-91. PubMed ID: 3119523
    [No Abstract]   [Full Text] [Related]  

  • 15. Coronary thrombolysis with tissue-type plasminogen activator.
    Bergmann SR; Ludbrook PA; Sobel BE
    Cardiol Clin; 1987 Feb; 5(1):101-11. PubMed ID: 3103916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
    Yamada S; Yamada R; Ishii A; Ashikawa K; Kawamitsu H; Fujita K
    J Cardiol; 1996 Apr; 27(4):171-8. PubMed ID: 8642503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue-type plasminogen activator alone or in combination with thromboxane A2 synthetase inhibitor for ischemic myocardium.
    Ogawa T; Miura T; Tsuchida A; Iwamoto T; Urabe K; Endoh A; Iimura O
    Can J Cardiol; 1990 Oct; 6(8):361-6. PubMed ID: 2125235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue plasminogen activator: a new thrombolytic agent.
    Crabbe SJ; Cloninger CC
    Clin Pharm; 1987 May; 6(5):373-86. PubMed ID: 3117481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial infarction and t-PA.
    N Engl J Med; 1988 Jun; 318(24):1617-8. PubMed ID: 3131675
    [No Abstract]   [Full Text] [Related]  

  • 20. Tissue-plasminogen activator: nursing implications.
    Briones TL
    Dimens Crit Care Nurs; 1989; 8(4):200-9. PubMed ID: 2505991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.